一个COVID-19主要蛋白酶抑制剂的分子生成模型,使用基于长期短期记忆的循环神经网络
Arash Mehrzadi1, Elham Rezaee2, Sajjad Gharaghani3
1Department of Electrical, Computer and IT Engineering, Qazvin Branch, Islamic Azad University, Qazvin, Iran.
概括
研究人员开发了一种深度学习模型,用于生成严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 的新型抑制剂. 这种人工智能方法成功识别了包括AADH在内的潜在药物化合物,显示了治疗2019年新冠肺炎 (COVID-19) 的前景.
科学领域:
- 计算化学是一种计算化学.
- 人工智能在药物发现中的作用
- 病毒学 病毒学
背景情况:
- 严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 构成了全球健康的重大威胁.
- 开发有效的抗病毒化合物对于对抗2019年冠状病毒病 (COVID-19) 至关重要.
研究的目的:
- 利用深度学习模型,特别是基于长期短期记忆的循环神经网络,用于生成针对SARS-CoV-2的新型抑制剂.
- 为了确定具有与SARS-CoV-2主蛋白酶显著结合亲和力的潜在候选药物.
主要方法:
- 训练一个循环神经网络来生成有效的简化分子输入线路输入系统 (SMILES) 字符串.
- 使用已知的COVID-19主要蛋白酶抑制剂结构微调模型.
- 使用分子对接和分子动力学模拟来评估结合亲和力和稳定性.
- 在体内进行ADMET (吸收,分布,新陈代谢,分泌) 研究.
主要成果:
- 微调模型成功生成了预测为SARS-CoV-2主要蛋白酶抑制剂的新型分子结构.
- 分子对接表明,对几个产生的化合物具有有利的结合亲和力.
- 分子动力学模拟提供了关于结合自由能量的见解.
- 在的ADMET研究表明,一些新型化合物的口服生物可用性.
- 化合物AADH显示出显著的结合亲和力和对SARS-CoV-2主要蛋白酶的潜在抑制.
结论:
- 拟议的深度学习模型有效地产生了有希望的抗COVID-19药物候选者.
- 化合物ADH显示出作为对抗SARS-CoV-2的治疗剂的潜力.
- 人工智能驱动的药物发现为识别新型抗病毒化合物提供了强大的方法.
相关概念视频
Retrovirus Life Cycles
46.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.0K
RNA Interference
26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K


